OACB.U / Oaktree Acquisition Corp. II - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-39526 Oaktree Acquisition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-39526 Oaktree Acquisition Corp. II The New York Stock Exchange (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or register

Filed by Alvotech (Commission File

Filed by Alvotech (Commission File No. 333-261773) Pursuant to Rule 425 under the Securities Act of 1933 And Deemed Filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Oaktree Acquisition Corp. II Press release STADA and Alvotech broaden European patients? options by launching Hukyndra? high-concentration, citrate-free adalimumab ? Hukyndra? offers a comprehens

Alvotech and Oaktree Acquisition Corp. II Announce Shareholder Approval of Business Combination

Exhibit 99.1 Alvotech and Oaktree Acquisition Corp. II Announce Shareholder Approval of Business Combination ? Business Combination anticipated to close on or about June 15, 2022 ? Ordinary shares of Alvotech expected to trade under the new ticker symbol ?ALVO? from June 16, 2022 on The Nasdaq Stock Market in New York and from June 23, 2022 on the Nasdaq First North Growth Market in Iceland ? Warr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 7, 2022 OAKTREE ACQUISITION CO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 7, 2022 OAKTREE ACQUISITION CORP.

Second Amendment to Business Combination Agreement, dated as of June 7, 2022, by and among Oaktree Acquisition Corp. II, Alvotech Holdings S.A. and Alvotech.

Exhibit 2.1 SECOND AMENDMENT TO BUSINESS COMBINATION AGREEMENT This SECOND AMENDMENT TO BUSINESS COMBINATION AGREEMENT (this ?Amendment?) is made as of June 7, 2022 by and between Alvotech Holdings S.A., a public limited liability company (soci?t? anonyme) incorporated and existing under the laws of the Grand Duchy of Luxembourg, having its registered office at 9, rue de Bitbourg, L-1273 Luxembour

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 7, 2022 OAKTREE ACQUISITION CORP.

Oaktree Acquisition Corp. II Announces Delisting of its Securities Effective and Conditional Upon Consummation of its Pending Business Combination with Alvotech Business Combination remains subject to satisfaction of customary closing conditions, inc

Exhibit 99.1 Oaktree Acquisition Corp. II Announces Delisting of its Securities Effective and Conditional Upon Consummation of its Pending Business Combination with Alvotech Business Combination remains subject to satisfaction of customary closing conditions, including approval of Oaktree?s shareholders Los Angeles (June 3, 2022) ? Oaktree Acquisition Corp. II (NYSE: OACB) (?OACB? or the ?Company?

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 3, 2022 Oaktree Acquisition Corp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 3, 2022 Oaktree Acquisition Co

425 1 d369078d425.htm 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 3, 2022 Oaktree Acquisition Corp. II (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-39526 98-1551592 (State or Other Jurisdiction o

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 31, 2022 Oaktree Acquisition Corp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 31, 2022 Oaktree Acquisition Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 31, 2022 Oaktree Acquisition Corp.

Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®

Filed by Alvotech (Commission File No. 333-261773) Pursuant to Rule 425 under the Securities Act of 1933 And Deemed Filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Oaktree Acquisition Corp. II Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara? ? The confirmatory clinical, saf

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 17, 2022 Oaktree Acquisition Corp.

This investor presentation (this “Presentation”) is for informational purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination (the “Business Combination”) between Oaktree Acquisition

Exhibit 99.1 INVESTOR PRESENTATION May 2022 This investor presentation (this ?Presentation?) is for informational purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination (the ?Business Combination?) between Oaktree Acquisition Corp. II (?SPAC?) and Alvotech Holdings S.A. (together with its subsidiaries, the ?Company?). The informa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 17, 2022 Oaktree Acquisition Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 17, 2022 Oaktree Acquisition Corp.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO

Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OAKTREE ACQUISITION CORP. II (Exact name of registrant as specified in it

Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara®

Filed by Alvotech Lux Holdings S.A.S. (Commission File No. 333-261773) Pursuant to Rule 425 under the Securities Act of 1933 And Deemed Filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Oaktree Acquisition Corp. II Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara? ? Results from pharmacoki

Alvotech, Global Biotech Company, and Oaktree Acquisition Corp. II Announce June 7, 2022 Extraordinary General Meeting to Approve Business Combination

Oaktree Acquisition Corp. II (Commission File No. 001-39526) Pursuant to Rule 425 under the Securities Act of 1933 And Deemed Filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Alvotech The following is a press release first made available on May 11, 2022. Alvotech, Global Biotech Company, and Oaktree Acquisition Corp. II Announce June 7, 2022 Extraordinary Ge

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 22, 2022 Oaktree Acquisition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 22, 2022 Oaktree Acquisition Corp.

First Amendment to the Business Combination Agreement, dated as of April 18, 2022, by and between Alvotech Holdings S.A. and Oaktree Acquisition Corp. II.

Exhibit 2.1 Execution Version FIRST AMENDMENT TO BUSINESS COMBINATION AGREEMENT This FIRST AMENDMENT TO BUSINESS COMBINATION AGREEMENT (this ?Amendment?) is made as of April 14, 2022 by and between Alvotech Holdings S.A., a public limited liability company (soci?t? anonyme) incorporated and existing under the laws of the Grand Duchy of Luxembourg, having its registered office at 9, rue de Bitbourg

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 22, 2022 Oaktree Acquisition Corp.

Alvotech Improves Access to Capital and Streamlines Path to Expected Public Listing on NASDAQ Stock Exchange Alvotech and Oaktree Acquisition Corp. II establish financing facilities to enhance the company’s capital position and to replace any redeeme

Filed by Alvotech Lux Holdings S.A.S. (Commission File No. 333-261773) Pursuant to Rule 425 under the Securities Act of 1933 And Deemed Filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Oaktree Acquisition Corp. II Alvotech Improves Access to Capital and Streamlines Path to Expected Public Listing on NASDAQ Stock Exchange Alvotech and Oaktree Acquisition Corp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 18, 2022 Oaktree Acquisition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 18, 2022 Oaktree Acquisition Corp.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 18, 2022 Oaktree Acquisition Corp.

Alvotech and STADA pave way to launching HUKYNDRA®(AVT02), a citrate-free, high-concentration biosimilar to Humira® by resolving European patent dispute with AbbVie

Exhibit 99.1 Press release Alvotech and STADA pave way to launching HUKYNDRA?(AVT02), a citrate-free, high-concentration biosimilar to Humira? by resolving European patent dispute with AbbVie ? Upon launch, HUKYNDRA? will be one of two citrate-free, high-concentration adalimumab biosimilars on the European market ? All intellectual-property disputes related to market entry of Alvotech?s AVT02 (ada

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 6, 2022 Oaktree Acquisition Corp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 6, 2022 Oaktree Acquisition C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 6, 2022 Oaktree Acquisition Corp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal period ended December 31, 2021 ☐ TRANSITION REPORT PURS

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal period ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 or 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Oaktree Acquisition Corp. II (E

This investor presentation (this “Presentation”) is for informational purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination (the “Business Combination”) between Oaktree Acquisition

Exhibit 99.1 ANALYST DAY MARCH 2022 This investor presentation (this ?Presentation?) is for informational purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination (the ?Business Combination?) between Oaktree Acquisition Corp. II (?SPAC?) and Alvotech Holdings S.A. (together with its subsidiaries, the ?Company?). The information con

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2022 Oaktree Acquisition Corp.

Filed by Alvotech Lux Holdings S.A.S. (Commission File No. 333-261773) Pursuant to Rule 425 under the Securities Act of 1933 And Deemed Filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Oaktree Acquisition Corp.

Filed by Alvotech Lux Holdings S.A.S. (Commission File No. 333-261773) Pursuant to Rule 425 under the Securities Act of 1933 And Deemed Filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Oaktree Acquisition Corp. II ANALYST DAY MARCH 2022 This investor presentation (this ?Presentation?) is for informational purposes only to assist interested parties in making

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2022 Oaktree Acquisition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2022 Oaktree Acquisition Corp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 8, 2022 Oaktree Acquisition C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 8, 2022 Oaktree Acquisition Corp.

Alvotech Resolves U.S. Patent and Trade Secret Disputes with AbbVie, Securing U.S. Rights for Alvotech’s Proposed High-Concentration Biosimilar (AVT02) for Humira® Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulator

Exhibit 99.1 Alvotech Resolves U.S. Patent and Trade Secret Disputes with AbbVie, Securing U.S. Rights for Alvotech?s Proposed High-Concentration Biosimilar (AVT02) for Humira? Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023 All ongoing U.S. disputes between AbbVie and Alvotech have been resolved, including the ITC action brought fo

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 8, 2022 Oaktree Acquisition Corp.

FDA Accepts Alvotech’s BLA Supporting Interchangeability for ATV02, a High Concentration, Citrate-Free Biosimilar Candidate for Humira® Alvotech is the only known company to have both developed a high-concentration biosimilar to Humira and conducted

Filed by Alvotech Lux Holdings S.A.S. (Commission File No. 333-261773) Pursuant to Rule 425 under the Securities Act of 1933 And Deemed Filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Oaktree Acquisition Corp. II FDA Accepts Alvotech?s BLA Supporting Interchangeability for ATV02, a High Concentration, Citrate-Free Biosimilar Candidate for Humira? Alvotech i

Alvotech and Fuji Pharma Expand Partnership for Additional Biosimilar Candidate in Japan Fuji and Alvotech partnership now covers six proposed biosimilar products

Filed by Alvotech Lux Holdings S.A.S. (Commission File No. 333-261773) Pursuant to Rule 425 under the Securities Act of 1933 And Deemed Filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Oaktree Acquisition Corp. II Alvotech and Fuji Pharma Expand Partnership for Additional Biosimilar Candidate in Japan Fuji and Alvotech partnership now covers six proposed bio

OACB / Oaktree Acquisition Corp. II / MILLENNIUM MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 OAKTREE ACQUISITION CORP. II (Name of Issuer) CLASS A ORDINARY SHARES, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) G6715X103 (CUSIP Number) FEBRUARY 10, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the r

Oaktree Acquisition Corp. II (Commission File No. 001-39526) Pursuant to Rule 425 under the Securities Act of 1933 And Deemed Filed und Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Alvotech Lux Holdings S.A.S. INVESTOR PRESE

Oaktree Acquisition Corp. II (Commission File No. 001-39526) Pursuant to Rule 425 under the Securities Act of 1933 And Deemed Filed und Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Alvotech Lux Holdings S.A.S. INVESTOR PRESENTATION February 2022 This investor presentation (this ?Presentation?) is for informational purposes only to assist interested parties in making their

OACB / Oaktree Acquisition Corp. II / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 2) OAKTREE ACQUISITION CORP. II (Name of Issuer) CLASS A ORDINARY SHARES, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) G6715X103 (CUSIP Number) DECEMBER 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box

Alvotech Enters Exclusive Global Licensing Agreement with BiosanaPharma for Co-Development of a Proposed Biosimilar (AVT23) to Xolair® (Omalizumab)

Filed by Alvotech Lux Holdings S.A.S. (Commission File No. 333-261773) Pursuant to Rule 425 under the Securities Act of 1933 And Deemed Filed und Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Oaktree Acquisition Corp. II Alvotech Enters Exclusive Global Licensing Agreement with BiosanaPharma for Co-Development of a Proposed Biosimilar (AVT23) to Xolair? (Omalizumab) REYKJA

Form of Additional Subscription Agreement.

Exhibit 10.1 Confidential FORM OF SUBSCRIPTION AGREEMENT Oaktree Acquisition Corp. II 333 South Grand Avenue, 28th Floor Los Angeles, CA 90071 Alvotech Lux Holdings S.A.S. 9, rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg Ladies and Gentlemen: This Subscription Agreement (this ?Subscription Agreement?) is being entered into as of the date set forth on the signature page hereto, by a

Alvotech Upsizes Oversubscribed PIPE Transaction to Approximately $175 Million

Exhibit 99.1 Alvotech Upsizes Oversubscribed PIPE Transaction to Approximately $175 Million Reykjavik (January 18, 2022) ? Alvotech Holdings S.A. (?Alvotech?), a leading global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Oaktree Acquisition Corp. II (?Oaktree II?) (NYSE: OACB), a publicly traded special purpose acq

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 18, 2022 Oaktree Acquisition Corp. II (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-39526 98-1551592 (State or Other Jurisdiction of Incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 18, 2022 Oaktree Acquisit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 18, 2022 Oaktree Acquisition Corp. II (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-39526 98-1551592 (State or Other Jurisdiction of Incorporation) (Co

JAMP and Alvotech Announce Canadian Approval of SIMLANDI™, a High-Concentration Biosimilar to Humira®, Providing Access to Previously Unavailable Versions in Canada Health Canada rules that 40 mg/0.4 mL and 80 mg/0.8 mL presentations of SIMLANDI™ are

Filed by Alvotech Lux Holdings S.A.S. (Commission File No. 333-261773) Pursuant to Rule 425 under the Securities Act of 1933 And Deemed Filed und Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Oaktree Acquisition Corp. II JAMP and Alvotech Announce Canadian Approval of SIMLANDI?, a High-Concentration Biosimilar to Humira?, Providing Access to Previously Unavailable Versions

AVT02, Alvotech’s Biosimilar to High Concentration Formulation of Adalimumab (Humira®) Approved for Use in European Union

Filed by Oaktree Acquisition Corp. II (Commission File No. 001-39526) Pursuant to Rule 425 under the Securities Act of 1933 And Deemed Filed und Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Alvotech Holdings S.A. AVT02, Alvotech?s Biosimilar to High Concentration Formulation of Adalimumab (Humira?) Approved for Use in European Union REYKJAVIK, ICELAND (DECEMBER 15, 2021)

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 14, 2021 Oaktree Acquisition Corp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal period ended December 31, 2020 ☐ TR

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal period ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Oaktree Acq

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 20

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to O

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2021 OAKTREE ACQUISITION CORP. II (Exact name of registrant as specified in its charter) Cayman Islands 001-39526 98-1551592 (State or other jurisdiction of inco

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2021 OAKTREE ACQUISITION CORP. II (Exact name of registrant as specified in its charter) Cayman Islands 001-39526 98-1551592 (State or other jurisdiction of incorp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 7, 2021 Oaktree Acquisitio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 7, 2021 Oaktree Acquisition Corp.

Sponsor Letter Agreement, dated as of December 7, 2021, by and among OACB, OACB Sponsor and TopCo

Exhibit 10.1 SPONSOR LETTER AGREEMENT This SPONSOR LETTER AGREEMENT (this ?Agreement?), dated as of December 7, 2021, is made by and among Oaktree Acquisition Holdings II, L.P., a Cayman Islands exempted limited partnership (the ?Sponsor?), Oaktree Acquisition Corp. II, a Cayman Islands exempted company (?Parent?), and Alvotech Lux Holdings S.A.S., a simplified joint stock company (soci?t? par act

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 7, 2021 Oaktree Acquisition Corp.

Form of Support Agreement

Exhibit 10.2 SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this ?Agreement?) is entered into as of [?], 2021, by and between Oaktree Acquisition Corp. II, a Cayman Islands exempted company (?Parent?), Alvotech Lux Holdings S.A.S., a simplified joint stock company (soci?t? par actions simplifi?e) incorporated and existing under the laws of the Grand Duchy of Luxembourg, with registered office at 9, rue

Form of Foreign Subscription Agreement

Exhibit 10.4 FORM OF SUBSCRIPTION AGREEMENT Oaktree Acquisition Corp. II 333 South Grand Avenue, 28th Floor Los Angeles, CA 90071 Alvotech Lux Holdings S.A.S. 9, rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg Ladies and Gentlemen: This Subscription Agreement (this ?Subscription Agreement?) is being entered into as of the date set forth on the signature page hereto, by and among Oakt

Alvotech and Oaktree Acquisition Corp. II Announce Merger Agreement to Create a Leading Publicly-Traded Global Biopharmaceutical Company

Exhibit 99.1 Alvotech and Oaktree Acquisition Corp. II Announce Merger Agreement to Create a Leading Publicly-Traded Global Biopharmaceutical Company ? Alvotech is a leading pure play biosimilar platform focused on the development and manufacture of high-quality biosimilar medicines for global markets. Biosimilars are therapeutic equivalents to biologics, a rapidly growing category of highly effic

INVESTOR PRESENTATION December 2021

Exhibit 99.2 INVESTOR PRESENTATION December 2021 This investor presentation (this ?Presentation?) is for informational purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination (the ?Business Combination?) between Oaktree Acquisition Corp. II (?SPAC?) and Alvotech Holdings S.A. (together with its subsidiaries, the ?Company?). The in

Business Combination Agreement, dated as of December 7, 2021, by and among OACB, Alvotech and TopCo

Exhibit 2.1 EXECUTION VERSION BUSINESS COMBINATION AGREEMENT BY AND AMONG ALVOTECH LUX HOLDINGS S.A.S., ALVOTECH HOLDINGS S.A., AND OAKTREE ACQUISITION CORP. II DATED AS OF DECEMBER 7, 2021 TABLE OF CONTENTS PAGE ARTICLE 1 CERTAIN DEFINITIONS 3 Section 1.1 Definitions 3 Section 1.2 Certain Defined Terms 15 ARTICLE 2 MERGERS 18 Section 2.1 Closing Transactions 18 Section 2.2 Allocation Schedule 21

Supplemental Unaudited Financial Information of Alvotech Holdings S.A.

Exhibit 99.4 Supplemental Unaudited Financial Information of Alvotech Holdings S.A. The historical supplemental unaudited financial information regarding Alvotech Holdings S.A. (the ?Parent? or the ?Company?) contained in this 8-K has been taken from or prepared based on historical financial information of the Company. These historical financial statements have not been audited. An audit of the Co

Form of U.S. Subscription Agreement

Exhibit 10.3 FORM OF SUBSCRIPTION AGREEMENT Oaktree Acquisition Corp. II 333 South Grand Avenue, 28th Floor Los Angeles, CA 90071 Alvotech Lux Holdings S.A.S. 9, rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg Ladies and Gentlemen: This Subscription Agreement (this ?Subscription Agreement?) is being entered into as of the date set forth on the signature page hereto, by and among Oakt

Slide #1 – Stephanie Carrington

Exhibit 99.3 Slide #1 ? Stephanie Carrington Hello and welcome to the investor webcast of management?s prepared remarks regarding the definitive merger agreement between Alvotech and Oaktree Acquisition Corp. II (or OACB for short). Slide #2-3 ? Stephanie Carrington The information discussed today is qualified in its entirety by the Form 8-K that has been filed today, December 7 by Oaktree Acquisi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION R

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OAKTREE ACQUISITION C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OAKTREE ACQUISITION CORP.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OAKTREE ACQUISITION CORP.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal period ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Oaktree Acq

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2021 ☐ Transi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: March 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 OAKTREE ACQUISITION CORP. II (Exact name of registrant as specified in its charter) Cayman Islands 001-39526 98-1551592 (State or other jurisdiction of incorporat

Description of Registrant’s Securities.(4)

Exhibit 4.2 OAKTREE ACQUISITION CORP. II DESCRIPTION OF SECURITIES The following summary of the material terms of the securities of Oaktree Acquisition Corp. II (?we,? ?us,? ?our? or ?the company?) is not intended to be a complete summary of the rights and preferences of such securities and is subject to and qualified by reference to our second amended and restated memorandum and articles of assoc

Code of Ethics.(4)

Exhibit 14.1 OAKTREE ACQUISITION CORP. II CODE OF ETHICS I. INTRODUCTION This Code of Ethics (the ?Code?) has been adopted pursuant to Section 303A.10 of the New York Stock Exchange (?NYSE?) Listed Company Manual. Under Section 303A.10, Oaktree Acquisition Corp. II (the ?Corporation?) must adopt a code of business conduct and ethics for directors, officers and employees. This Code is intended to f

Annual Report - 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal period ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Oaktree Acquisition Corp. II (E

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned acknowledges and agrees that the foregoing statement on this Schedule 13G is filed on behalf of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of the undersigned without the necessity of filing additional joint acquisition statements.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 Oaktree Acquisition Corp. II (Name of Issuer) CLASS A ORDINARY SHARES, PAR VALUE $0.0001 (Title of Class of Securities) G67

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 Oaktree Acquisition Corp. II (Name of Issuer) CLASS A ORDINARY SHARES, PAR VALUE $0.0001 (Title of Class of Securities) G6715X 103 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the Appropriate Box to Designate the Rul

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) OAKTREE ACQUISITION CORP. II (Name of Issuer) CLASS A ORDINARY SHARES, PAR VALUE $0.0001 PER SHARE (Title

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) OAKTREE ACQUISITION CORP. II (Name of Issuer) CLASS A ORDINARY SHARES, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) G6715X103 (CUSIP Number) DECEMBER 31, 2020 (Date of event which requires filing of this statement) Check the appropriate box

Quarterly Report - 10-Q

10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Financial Statements and Exhibits, Other Events - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 OAKTREE ACQUISITION CORP. II (Exact name of registrant as specified in its charter) Cayman Islands 001-39526 98-1551592 (State or other jurisdiction of in

Oaktree Acquisition Corp. II Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing November 9, 2020

EX-99.1 Exhibit 99.1 Oaktree Acquisition Corp. II Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing November 9, 2020 LOS ANGELES, November 9, 2020—(BUSINESS WIRE)—Oaktree Acquisition Corp. II (NYSE: OACB.U) (the “Company”) announced that, commencing November 9, 2020, holders of the units sold in the Company’s initial public offering of 25,000,000 units, complete

OAKTREE ACQUISITION CORP. II Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Financial Statement F-4

EX-99.1 Exhibit 99.1 OAKTREE ACQUISITION CORP. II Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Financial Statement F-4 Report of Independent Registered Public Accounting Firm To the Shareholders and the Board of Directors of Oaktree Acquisition Corp. II Opinion on the Financial Statement We have audited the accompanying balance sheet of Oaktree Acquisition

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2020 OAKTREE ACQUISITION CORP. II (Exact name of registrant as specified in its charter) Cayman Islands 001-39526 98-1551592 (State or other jurisdiction of inco

Private Placement Warrants Purchase Agreement, dated as of September 16, 2020, between the Company and the Sponsor.(2)

EX-10.1 Exhibit 10.1 EXECUTION VERSION PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT THIS PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT (as it may from time to time be amended and including all exhibits referenced herein, this “Agreement”), dated as of September 16, 2020, is entered into by and between Oaktree Acquisition Corp. II, a Cayman Islands exempted company (the “Company”), and Oaktree Acq

Form of Letter Agreement between the Company and each of the officers and directors of the Company.(2)

EX-10.4 Exhibit 10.4 September 21, 2020 Oaktree Acquisition Corp. II 333 South Grand Avenue, 28th Floor Los Angeles, CA 90071 Deutsche Bank Securities Inc. 60 Wall Street, 4th Floor New York, New York 10005 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10022 Re: Initial Public Offering Ladies and Gentlemen: This letter (the “Letter Agreement”) is being delivered to you in a

Warrant Agreement, dated as of September 21, 2020, between Continental Stock Transfer & Trust Company and the Company.(2)

EX-4.1 Exhibit 4.1 WARRANT AGREEMENT between OAKTREE ACQUISITION CORP. II and CONTINENTAL STOCK TRANSFER & TRUST COMPANY THIS WARRANT AGREEMENT (this “Agreement”), dated as of September 21, 2020, is by and between Oaktree Acquisition Corp. II, a Cayman Islands exempted company (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (the “Warrant Ag

Investment Management Trust Account Agreement, dated as of September 21, 2020, between Continental Stock Transfer & Trust Company and the Company.(2)

EX-10.2 Exhibit 10.2 EXECUTION VERSION INVESTMENT MANAGEMENT TRUST AGREEMENT This Investment Management Trust Agreement (this “Agreement”) is made as of September 21, 2020 by and between Oaktree Acquisition Corp. II (the “Company”) and Continental Stock Transfer & Trust Company, a New York corporation (the “Trustee”). WHEREAS, the Company’s registration statement on Form S-1, No. 333-248508 (“Regi

Letter Agreement, dated as of September 21, 2020, between the Company and the Sponsor.(2)

EX-10.5 Exhibit 10.5 September 21, 2020 Oaktree Acquisition Corp. II 333 South Grand Avenue, 28th Floor Los Angeles, CA 90071 Deutsche Bank Securities Inc. 60 Wall Street, 4th Floor New York, New York 10005 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10022 Re: Initial Public Offering Ladies and Gentlemen: This letter (the “Letter Agreement”) is being delivered to you in a

Underwriting Agreement, dated as of September 16, 2020, among the Company and Deutsche Bank Securities Inc. and Citigroup Global Markets Inc., as representatives of the several underwriters

EX-1.1 Exhibit 1.1 EXECUTION VERSION 22,500,000 Units Oaktree Acquisition Corp. II UNDERWRITING AGREEMENT September 16, 2020 Deutsche Bank Securities Inc. 60 Wall Street New York, New York 10005 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10022 As Representatives of the several Underwriters Ladies and Gentlemen: Oaktree Acquisition Corp. II, a Cayman Islands exempted comp

Registration and Shareholder Rights Agreement, dated as of September 21, 2020, between the Company and the Sponsor.(2)

EX-10.3 Exhibit 10.3 EXECUTION VERSION REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT THIS REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT (this “Agreement”) is entered into as of September 21, 2020, by Oaktree Acquisition Corp. II, a Cayman Islands exempted company (the “Company”), and Oaktree Acquisition Holdings II, L.P., a Cayman Islands exempted limited partnership (the “Sponsor” and, together w

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2020 OAKTREE ACQUISITION CORP. II (Exact name of registrant as specified in its charter) Cayman Islands 001-39526 98-1551592 (State or other jurisdiction of inco

Administrative Services Agreement, dated as of September 21, 2020, between the Company and the Sponsor.(2)

EX-10.6 Exhibit 10.6 EXECUTION VERSION OAKTREE ACQUISITION CORP. II 333 South Grand Avenue, 28th Floor Los Angeles, CA 90071 September 21, 2020 Oaktree Acquisition Holdings II, L.P. 333 South Grand Avenue, 28th Floor Los Angeles, CA 90071 Ladies and Gentlemen: This letter will confirm our agreement that, commencing on the effective date (the “Effective Date”) of the registration statement (the “Re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 OAKTREE ACQUISITION CORP. II (Name of Issuer) CLASS A ORDINARY SHARES, PAR VALUE $0.0001 PER SHARE (Title of Class of Secur

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 OAKTREE ACQUISITION CORP. II (Name of Issuer) CLASS A ORDINARY SHARES, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) G6715X129** (CUSIP Number) SEPTEMBER 17, 2020 (Date of event which requires filing of this statement) Check the appropriate box to designate th

TABLE OF CONTENTS Page SUMMARY 1 SUMMARY FINANCIAL DATA 36 RISK FACTORS 37 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 78 USE OF PROCEEDS 79 DIVIDEND POLICY 82 DILUTION 83 CAPITALIZATION 85 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL C

424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-248508 PROSPECTUS Oaktree Acquisition Corp. II $225,000,000 22,500,000 Units Oaktree Acquisition Corp. II is a newly formed blank check company incorporated as a Cayman Islands exempted company and formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar b

- 8-A12B

8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OAKTREE ACQUISITION CORP.

Specimen Warrant Certificate.**

EX-4.3 Exhibit 4.3 Form of Warrant Certificate [FACE] Number Warrants THIS WARRANT SHALL BE VOID IF NOT EXERCISED PRIOR TO THE EXPIRATION OF THE EXERCISE PERIOD PROVIDED FOR IN THE WARRANT AGREEMENT DESCRIBED BELOW OAKTREE ACQUISITION CORP. II A Cayman Islands Exempted Company CUSIP [●] Warrant Certificate This Warrant Certificate certifies that [], or registered assigns, is the registered holder

Form of Underwriting Agreement.**

EX-1.1 Exhibit 1.1 22,500,000 Units Oaktree Acquisition Corp. II UNDERWRITING AGREEMENT September [•], 2020 Deutsche Bank Securities Inc. 60 Wall Street New York, New York 10005 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10022 As Representatives of the several Underwriters Ladies and Gentlemen: Oaktree Acquisition Corp. II, a Cayman Islands exempted company (the “Company

Form of Warrant Agreement between Continental Stock Transfer & Trust Company and the Registrant.**

EX-4.4 Exhibit 4.4 WARRANT AGREEMENT between OAKTREE ACQUISITION CORP. II and CONTINENTAL STOCK TRANSFER & TRUST COMPANY THIS WARRANT AGREEMENT (this “Agreement”), dated as of [•], 2020, is by and between Oaktree Acquisition Corp. II, a Cayman Islands exempted company (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (the “Warrant Agent”, als

Second Amended and Restated Memorandum and Articles of Association.(1)

EX-3.2 Exhibit 3.2 THE COMPANIES LAW (AS AMENDED) COMPANY LIMITED BY SHARES SECOND AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF OAKTREE ACQUISITION CORP. II (ADOPTED BY SPECIAL RESOLUTION DATED [] 2020) THE COMPANIES LAW (AS AMENDED) COMPANY LIMITED BY SHARES SECOND AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF OAKTREE ACQUISITION CORP. II (ADOPTED BY SPECIAL RESOLUTION DATED [] 2020) 1.

- S-1/A

S-1/A Table of Contents Filed with the U.S. Securities and Exchange Commission on September 14, 2020 under the Securities Act of 1933, as amended. No. 333-248508 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Oaktree Acquisition Corp. II (Exact name of registrant as specified in its charter

Form of Investment Management Trust Agreement between Continental Stock Transfer & Trust Company and the Registrant.

Exhibit 10.1 INVESTMENT MANAGEMENT TRUST AGREEMENT This Investment Management Trust Agreement (this ?Agreement?) is made as of [?], 2020 by and between Oaktree Acquisition Corp. II (the ?Company?) and Continental Stock Transfer & Trust Company, a New York corporation (the ?Trustee?). WHEREAS, the Company?s registration statement on Form S-1, No. 333-[?] (?Registration Statement?), for its initial

Memorandum and Articles of Association.

Exhibit 3.1 THE COMPANIES LAW (AS AMENDED) COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF OAKTREE ACQUISITION CORP. II (AMENDED BY SPECIAL RESOLUTION DATED 10 AUGUST 2020) THE COMPANIES LAW (AS AMENDED) COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF OAKTREE ACQUISITION CORP. II (AMENDED BY SPECIAL RESOLUTION DATED 10 AUGUST 202

Specimen Unit Certificate.

Exhibit 4.1 SPECIMEN UNIT CERTIFICATE NUMBER UNITS U- SEE REVERSE FOR CERTAIN DEFINITIONS Oaktree Acquisition Corp. II CUSIP [ ] UNITS CONSISTING OF ONE CLASS A ORDINARY SHARE AND ONE-FOURTH OF ONE WARRANT TO PURCHASE ONE CLASS A ORDINARY SHARE THIS CERTIFIES THAT is the owner of Units. Each Unit (?Unit?) consists of one (1) Class A ordinary share, par value $0.0001 per share (?Ordinary Shares?),

Consent of Andrea Wong.

Exhibit 99.3 CONSENT OF ANDREA WONG Oaktree Acquisition Corp. II (the ?Company?) intends to file a Registration Statement on Form S-1 (together with any amendments or supplements thereto, the ?Registration Statement?) registering securities for issuance in its initial public offering. As required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby consents to being nam

Certificate of Incorporation.

Exhibit 3.3 Authorisation Code : 471186326784 www.verify.gov.ky 10 August 2020 WC-364940 Certificate of Incorporation on Change of Name I DO HEREBY CERTIFY that Given under my hand and Seal at George Town in the Island of Grand Cayman this 10th day of August Two Thousand Twenty An Authorised Officer, Registry of Companies, having by Special resolution dated 10th day of August Two Thousand Twenty c

Form of Registration and Shareholder Rights Agreement among the Registrant, the Sponsor and the Holders signatory thereto.

Exhibit 10.2 REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT THIS REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT (this ?Agreement?) is entered into as of [?], 2020, by Oaktree Acquisition Corp. II, a Cayman Islands exempted company (the ?Company?), and Oaktree Acquisition Holdings II, L.P., a Cayman Islands exempted limited partnership (the ?Sponsor? and, together with any person or entity who hereaf

Form of Private Placement Warrants Purchase Agreement between the Registrant and the Sponsor.

Exhibit 10.3 PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT THIS PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT (as it may from time to time be amended and including all exhibits referenced herein, this ?Agreement?), dated as of [?], 2020, is entered into by and between Oaktree Acquisition Corp. II, a Cayman Islands exempted company (the ?Company?), and Oaktree Acquisition Holdings II, L.P., a Cayma

Form of Letter Agreement among the Registrant and each director and executive officer of the Registrant.

Exhibit 10.9 [?], 2020 Oaktree Acquisition Corp. II 333 South Grand Avenue, 28th Floor Los Angeles, CA 90071 Deutsche Bank Securities Inc. 60 Wall Street, 4th Floor New York, New York 10005 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10022 Re: Initial Public Offering Ladies and Gentlemen: This letter (the ?Letter Agreement?) is being delivered to you in accordance with th

Form of Administrative Services Agreement between the Registrant and the Sponsor.

EX-10.5 Exhibit 10.5 OAKTREE ACQUISITION CORP. II 333 South Grand Avenue, 28th Floor Los Angeles, CA 90071 [●], 2020 Oaktree Acquisition Holdings II, L.P. 333 South Grand Avenue, 28th Floor Los Angeles, CA 90071 Ladies and Gentlemen: This letter will confirm our agreement that, commencing on the effective date (the “Effective Date”) of the registration statement (the “Registration Statement”) for

Securities Subscription Agreement, dated August 7, 2020, between the Company and the Sponsor.(3)

Exhibit 10.7 Oaktree Acquisition Corp. II 333 South Grand Avenue 28th Floor Los Angeles, CA 90071 August 7, 2020 Oaktree Acquisition Holdings II, L.P. 333 South Grand Avenue 28th Floor Los Angeles, CA 90071 RE: Securities Subscription Agreement Gentlemen: This agreement (this ?Agreement?) is entered into on August 7, 2020 by and between Oaktree Acquisition Holdings II, L.P., a Cayman Islands exemp

Expense Reimbursement Agreement, dated as of August 7, 2020, between the Company and the Sponsor.(3)

Exhibit 10.6 EXPENSE REIMBURSEMENT AGREEMENT This EXPENSE REIMBURSEMENT AGREEMENT (this ?AGREEMENT?) is made as of August 7, 2020 by and between Oaktree Acquisition Holdings II, L.P., a Cayman Islands exempted limited partnership (?Sponsor?), and Oaktree Acquisition Corp. II, a Cayman Islands exempted company (the ?Company?) (collectively referred to herein as the ?Parties?, and each a ?Party?). W

Form of Indemnity Agreement.

Exhibit 10.4 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this ?Agreement?) is made as of [?], 2020, by and between Oaktree Acquisition Corp. II, a Cayman Islands exempted company (the ?Company?), and [?] (?Indemnitee?). WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless they are provided with adequ

Consent of Paul Meister.

Exhibit 99.2 CONSENT OF PAUL MEISTER Oaktree Acquisition Corp. II (the ?Company?) intends to file a Registration Statement on Form S-1 (together with any amendments or supplements thereto, the ?Registration Statement?) registering securities for issuance in its initial public offering. As required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby consents to being na

Specimen Ordinary Share Certificate.

Exhibit 4.2 SPECIMEN CLASS A ORDINARY SHARE CERTIFICATE NUMBER SHARES OAKTREE ACQUISITION CORP. II INCORPORATED UNDER THE LAWS OF THE CAYMAN ISLANDS CLASS A ORDINARY SHARES SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP [ ] This Certifies that is the owner of FULLY PAID AND NON-ASSESSABLE CLASS A ORDINARY SHARES, PAR VALUE $0.0001 EACH, OF OAKTREE ACQUISITION CORP. II (THE ?COMPANY?) transferable on th

Consent of Anthony Grillo.

EX-99.1 Exhibit 99.1 CONSENT OF ANTHONY GRILLO Oaktree Acquisition Corp. II (the “Company”) intends to file a Registration Statement on Form S-1 (together with any amendments or supplements thereto, the “Registration Statement”) registering securities for issuance in its initial public offering. As required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby consents t

Form of Letter Agreement between the Registrant and the Sponsor.

Exhibit 10.8 [?], 2020 Oaktree Acquisition Corp. II 333 South Grand Avenue, 28th Floor Los Angeles, CA 90071 Deutsche Bank Securities Inc. 60 Wall Street, 4th Floor New York, New York 10005 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10022 Re: Initial Public Offering Ladies and Gentlemen: This letter (the ?Letter Agreement?) is being delivered to you in accordance with th

Form S-1

Table of Contents Filed with the U.S. Securities and Exchange Commission on August 31, 2020 under the Securities Act of 1933, as amended. No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Oaktree Acquisition Corp. II (Exact name of registrant as specified in its charter) Cayman Islands 6770 98-1551592 (

-

DRS Table of Contents Confidential draft submitted to the U.S. Securities and Exchange Commission on August 13, 2020. This draft registration statement has not been publicly filed with the U.S. Securities and Exchange Commission and all information herein remains strictly confidential. No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT